Could a Starch-Based drug clean toxins from dialysis Patients' blood?

NCT ID NCT07653711

Recruiting now Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests whether a drug called coated aldehyde oxystarch (Xiqing) can reduce protein-bound uremic toxins in adults with end-stage renal disease who are on dialysis. Participants take the drug three times daily for three months. Researchers measure toxin levels in the blood before and after treatment to see if they drop.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Coated Aldehyde Oxystarch (Xiqing)
What this could lead to: If it works, this could offer a new way to reduce harmful toxins in dialysis patients, potentially improving their health and quality of life.
What could go wrong: This is a small, early exploratory trial with only 30 participants, so results may not apply broadly. The treatment may not lower toxins enough to make a difference, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE ON DIALYSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END STAGE RENAL DISEASE ON DIALYSIS

Contacts and locations

Locations

Peking University People's Hospital
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.